Study Evaluating Long-Term Safety of Effexor XR in Patients With Major Depression.

NCT ID: NCT00225524

Last Updated: 2007-05-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Phase III long-term safety study of Effexor XR in patients with major depression.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Effexor XR

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who complete the Phase III double-blind study (Protocol Number 0600B1-816)

Exclusion Criteria

* Patients with schizophrenia or any other psychotic disorder
* Patients with history or presence of bipolar disorder
Minimum Eligible Age

20 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Monitor

Role: STUDY_DIRECTOR

Wyeth is now a wholly owned subsidiary of Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Nagoya, Aichi-ken, Japan

Site Status

Nagoya, Aichi-ken, Japan

Site Status

Ichikawa, Chiba, Japan

Site Status

Ichikawa, Chiba, Japan

Site Status

Fukuoka, Fukuoka, Japan

Site Status

Fukuoka, Fukuoka, Japan

Site Status

Fukuoka, Fukuoka, Japan

Site Status

Fukuoka, Fukuoka, Japan

Site Status

Kasuga, Fukuoka, Japan

Site Status

Kitakyushu, Fukuoka, Japan

Site Status

Kitakyushu, Fukuoka, Japan

Site Status

Kitakyushu, Fukuoka, Japan

Site Status

Kurume, Fukuoka, Japan

Site Status

Ohnojyo, Fukuoka, Japan

Site Status

Hiroshima, Hiroshima, Japan

Site Status

Hiroshima, Hiroshima, Japan

Site Status

Hiroshima, Hiroshima, Japan

Site Status

Kure, Hiroshima, Japan

Site Status

Otaru, Hokkaido, Japan

Site Status

Sapporo, Hokkaido, Japan

Site Status

Sapporo, Hokkaido, Japan

Site Status

Sapporo, Hokkaido, Japan

Site Status

Sapporo, Hokkaido, Japan

Site Status

Sapporo, Hokkaido, Japan

Site Status

Sapporo, Hokkaido, Japan

Site Status

Nishinomiya, Hyōgo, Japan

Site Status

Tsuchiura, Ibaragi, Japan

Site Status

Tsukuba, Ibaragi, Japan

Site Status

Kanazawa, Ishikawa-ken, Japan

Site Status

Hanamaki, Iwate, Japan

Site Status

Kawasaki, Kanagawa, Japan

Site Status

Kawasaki, Kanagawa, Japan

Site Status

Sagamihara, Kanagawa, Japan

Site Status

Sagamihara, Kanagawa, Japan

Site Status

Yokohama, Kanagawa, Japan

Site Status

Yokohama, Kanagawa, Japan

Site Status

Yokohama, Kanagawa, Japan

Site Status

Yokohama, Kanagawa, Japan

Site Status

Yokohama, Kanagawa, Japan

Site Status

Yokohama, Kanagawa, Japan

Site Status

Yokosuka, Kanagawa, Japan

Site Status

Kikuchi, Kumamoto, Japan

Site Status

Nagasaki, Nagasaki, Japan

Site Status

Ohmura, Nagasaki, Japan

Site Status

Kashihara, Nara, Japan

Site Status

Jyo-etsu, Niigata, Japan

Site Status

Beppu, Ohita, Japan

Site Status

Moriguchi, Osaka, Japan

Site Status

Osaka, Osaka, Japan

Site Status

Osaka, Osaka, Japan

Site Status

Sayama, Osaka, Japan

Site Status

Sayama, Osaka, Japan

Site Status

Saitama, Saitama, Japan

Site Status

Hamamatsu, Shizuoka, Japan

Site Status

Adachi-ku, Tokyo, Japan

Site Status

Bunkyo-ku, Tokyo, Japan

Site Status

Bunkyo-ku, Tokyo, Japan

Site Status

Chiyoda-ku, Tokyo, Japan

Site Status

Chiyoda-ku, Tokyo, Japan

Site Status

Itabashi-ku, Tokyo, Japan

Site Status

Kodaira, Tokyo, Japan

Site Status

Meguro-ku, Tokyo, Japan

Site Status

Meguro-ku, Tokyo, Japan

Site Status

Meguro-ku, Tokyo, Japan

Site Status

Minato-ku, Tokyo, Japan

Site Status

Minato-ku, Tokyo, Japan

Site Status

Nakano-ku, Tokyo, Japan

Site Status

Ohta-ku, Tokyo, Japan

Site Status

Setagaya-ku, Tokyo, Japan

Site Status

Shinjuku, Tokyo, Japan

Site Status

Tachikawa, Tokyo, Japan

Site Status

Toshima-ku, Tokyo, Japan

Site Status

Toshima-ku, Tokyo, Japan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Japan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0600B1-818

Identifier Type: -

Identifier Source: org_study_id